Aldeyra Therapeutics, Inc.
ALDX
$1.52
-$0.03-1.62%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -57.86% | 46.57% | 15.96% | 21.29% | 1.63% |
| Total Depreciation and Amortization | 6.16% | 2.30% | 2.20% | 2.25% | 2.30% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -100.00% |
| Total Other Non-Cash Items | 275.31% | -185.48% | -53.63% | 1,396.38% | -109.69% |
| Change in Net Operating Assets | -8.39% | -112,514.29% | 100.04% | -232.20% | 128.05% |
| Cash from Operations | 10.19% | 3.57% | 24.53% | 17.93% | 31.39% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -36.00% | 4,611.82% | -107.60% |
| Cash from Investing | -- | -- | -36.00% | 4,611.82% | -107.60% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -- | -100.00% | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -21,618.99% | -- | -100.00% | -- | -100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -295.18% | -147.09% | -40.88% | 298.69% | -118.11% |